Lu AF35700

Drug Profile

Lu AF35700

Alternative Names: Lu AF356152 prodrug; Lu-AF35700

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Lundbeck A/S
  • Class Neuropsychotherapeutics
  • Mechanism of Action Dopamine D2 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Schizophrenia
  • Phase I Schizoaffective disorder

Most Recent Events

  • 01 Sep 2016 Phase-I clinical trials in Schizoaffective disorder in USA (PO) (NCT02901587)
  • 01 Sep 2016 Lundbeck initiates a phase I trial in Schizophrenia in USA (NCT02901587)
  • 11 Mar 2016 Phase-III clinical trials in Schizophrenia (Treatment-resistant) in USA, Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top